Apramycin (200 mg/kg/d, s.c., 9 d) demonstrates significant in vivo efficacy in lungs of M. tuberculosis low-dose aerosol infection model IFN-γ knockout mice[2].
Apramycin (16, 32, 80 mg/kg, s.c., 24 h) dose-dependently reduces bacterial burden in the kidneys between 2-5 log10 and in blood between 2-3 log10 for neutropenic model of Staphylococcus aureus septicemia mice[2].
Apramycin (50 mg/kg/d, s.c., 21 d) induces nephrotoxicity scores comparable to those induced by Gentamicin (10 mg/kg/d)[3].
| Animal Model: | M. tuberculosis low-dose aerosol infection model of IFN-γ knockout mice [2] |
| Dosage: | 200 mg/kg/d |
| Administration: | Subcutaneousinjection (s.c.) for 9 d |
| Result: | Showed a 2.4-log10 CFU reduction and better antituberculous activity compared to Amikacin (1.8-log10 reduction). |
